(Reuters) -All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals, whose medicines are part of the second ...

Wegovy contains the same main ingredient as Ozempic, semaglutide, and is FDA-approved for weight loss in people with obesity or who are overweight with at least one weight-related condition. It is ...

Tirzepatide — a drug that acts both as a GLP-1 agonist and a GIP agonist — is the active ingredient in an even more powerful ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...

Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.

Scientists have identified the Plvap gene as a key regulator of metabolism during fasting. Disabling it in mice prevented the ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.

BRINP2-related peptide, or BRP, is a naturally occurring molecule that can suppress appetite and promote weight loss in mice ...